Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...
Strategy likely has about $80M in cash and roughly $150M in dividend obligations due before the end of the year. Read more ...
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...
First Merchants delivers solid earnings growth, with net interest income rising and a well-covered 4% dividend yield. See why ...
Walmart (WMT) announced it will transfer the listing of its common stock to Nasdaq. The company expects its common stock to begin trading on the ...
It’s not very common to see a stock skyrocket over 2,600% in just three years. But that’s exactly what Celestica (TSX:CLS ...
The investment portfolios of Marjorie Taylor Greene and Warren Buffett's Berkshire Hathaway have some overlap with nine ...
"More professionals today are building wealth through equity compensation like stock options, restricted stock units, and ...
Nvidia may be the most popular chip stock right now, but smart investors are beginning to look for growth elsewhere.
The notes will be convertible under certain circumstances, with Eos having the option to settle conversions in cash, shares of common stock, or a combination of both. However, until Eos increases its ...
Unlike strategies that sacrifice future growth in favour of dividends, the Fund is designed to focus on long-term return while paying steady, tax-efficient monthly distributions. JPYS uses a ...